Intercept Pharma (ICPT) Posts Mixed Q2 Results: Updates on Ocaliva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
August 4, 2016 7:05 AM EDTOcaliva® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenueREGENERATE NASH trial targeted to complete enrollment for interim analysis in 1H17
Conference call scheduled for 8:30 am ET today      Â
NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel... More
